Cholesterol lowering: Perspectives on the 4S and West of Scotland studies

Cleveland Clinic Journal of Medicine

Volumn 63, Issue 2, 1996, Pages 80-83

  Olin, Jeffrey W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; SHORT SURVEY;

EID: 0029962850     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.63.2.80     Document Type: Short Survey

References (19)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
3. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1329-1445.
4. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
5. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994;14:177-192.
6. Lipid Research Clinics Program. The Lipid Research Clinics Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364.
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction and incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-374.
8. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study. Primary Prevention Trial with gemfibrozil in middle-aged men with dyslipidemia Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
9. Wysowski DK, Gross TP. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med 1990; 150:2169-2172.
10. Cummings P, Psaty BM. The association between cholesterol and death from injury. Ann Intern Med 1994; 120:848-855.
11. Chait A. The high-risk strategy for adults. In: Rifkind BM, ed. Lowering cholesterol in high-risk individuals and populations. New York: Marcel Dekker, Inc; 1995:22-23.
12. Jacobs D, Blackburn H, Higgins M, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86.1046-1060
13. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275:55-60.
14. Dalen JE, Dalton WS. Does lowering cholesterol cause cancer? JAMA 1996, 275:67-69
15. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? Br Med J 1992;304:431-434.
16. Kritchevsky SB, Kritchevsky D. Serum cholesterol and cancer risk: an epidemiologic perspective. Ann Rev Nutr 1992; 12:391-416.
17. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. Br Med J 1994, 308:373-379.
18. Committee of the Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984;2:600-604.
19. Pearce ML, Dayton S. Incidence of cancer in men on a diet high in polyunsaturated fat. Lancet 1971; 1:1464-1467.